CHRM4/AKT/MYCN upregulates interferon alpha-17 in the tumor microenvironment to promote neuroendocrine differentiation of prostate cancer
Open Access
- 4 May 2023
- journal article
- research article
- Published by Springer Nature in Cell Death & Disease
- Vol. 14 (5) , 1-15
Abstract
Current treatment options for prostate cancer focus on targeting androgen receptor (AR) signaling. Inhibiting effects of AR may activate neuroendocrine differentiation and lineage plasticity pathways, thereby promoting the development of neuroendocrine prostate cancer (NEPC). Understanding the regulatory mechanisms of AR has important clinical implications for this most aggressive type of prostate cancer. Here, we demonstrated the tumor-suppressive role of the AR and found that activated AR could directly bind to the regulatory sequence of muscarinic acetylcholine receptor 4 (CHRM4) and downregulate its expression. CHRM4 was highly expressed in prostate cancer cells after androgen-deprivation therapy (ADT). CHRM4 overexpression may drive neuroendocrine differentiation of prostate cancer cells and is associated with immunosuppressive cytokine responses in the tumor microenvironment (TME) of prostate cancer. Mechanistically, CHRM4-driven AKT/MYCN signaling upregulated the interferon alpha 17 (IFNA17) cytokine in the prostate cancer TME after ADT. IFNA17 mediates a feedback mechanism in the TME by activating the CHRM4/AKT/MYCN signaling-driven immune checkpoint pathway and neuroendocrine differentiation of prostate cancer cells. We explored the therapeutic efficacy of targeting CHRM4 as a potential treatment for NEPC and evaluated IFNA17 secretion in the TME as a possible predictive prognostic biomarker for NEPC.Keywords
Funding Information
- National Health Research Institutes (NHRI-EX111-11109BI)
- National Science and Technology Council, Taiwan
This publication has 39 references indexed in Scilit:
- Macrophages induce neuroendocrine differentiation of prostate cancer cells via BMP6‐IL6 LoopThe Prostate, 2011
- Androgen receptor levels are upregulated by Akt in prostate cancerEndocrine-Related Cancer, 2011
- Molecular genetics of prostate cancer: new prospects for old challengesGenes & Development, 2010
- Global MYCN Transcription Factor Binding Analysis in Neuroblastoma Reveals Association with Distinct E-Box Motifs and Regions of DNA HypermethylationPLOS ONE, 2009
- Phase 1 Trial of High-Dose Exogenous Testosterone in Patients with Castration-Resistant Metastatic Prostate CancerEuropean Urology, 2009
- Enhanced anti-HCV activity of interferon alpha 17 subtypeVirology Journal, 2009
- Identification of genes targeted by the androgen and PKA signaling pathways in prostate cancer cellsOncogene, 2006
- Increased Expression of Genes Converting Adrenal Androgens to Testosterone in Androgen-Independent Prostate CancerCancer Research, 2006
- Interferon, alpha 17 (IFNA17) Ile184Arg polymorphism and cervical cancer riskCancer Letters, 2003
- Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1.Journal of Experimental Medicine, 1994